RAS Drug Nearly Doubles Survival in Mets Pancreatic Cancer

by | Jun 3, 2026 | Health

In a 500-patient phase 3 trial, daraxonrasib extends median overall survival to 13.2 vs 6.7 months for chemotherapy in second-line metastatic pancreatic cancer.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments